Pfizer

Pfizer Inc.
Company type	Public
Traded as	NYSE: PFE; S&P 100 component; S&P 500 component;
Industry	Pharmaceutical; Biotechnology;
Founded	1849 in New York City
Founders	Charles Pfizer; Charles F. Erhart;
Headquarters	The Spiral, New York City, U.S.
Area served	Worldwide
Key people	Albert Bourla (CEO)
Products	Pharmaceutical drugs; vaccines;
Revenue	US$58.5 billion (2023)
Operating income	US$2.17 billion (2023)
Net income	US$2.12 billion (2023)
Total assets	US$226.5 billion (2023)
Total equity	US$89.01 billion (2023)
Number of employees	c. 88,000 (2023)
Website	pfizer.com
	Footnotes / references;

Former corporate logos (until 2021).

Pfizer Inc. (/ˈfaɪzər/ FY-zər)^[3] is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company's largest products by sales are the Pfizer–BioNTech COVID-19 vaccine ($11 billion in 2023 revenues), apixaban ($6 billion in 2023 revenues), a pneumococcal conjugate vaccine ($6 billion in 2023 revenues), palbociclib ($4 billion in 2023 revenues), and tafamidis ($3 billion in 2023 revenues).^[1] In 2023, 46% of the company's revenues came from the United States, 6% came from Japan, and 48% came from other countries.^[1]

The company ranks 38th on the Fortune 500^[4] and 39th on the Forbes Global 2000.^[5]